FEATURE ARTICLES
Vapor phase hydrogen peroxide has been used for decades as a surface decontaminant in pharma/biotech, but there has been little guidance on how to establish the parameters. Here's an industry consensus from BioPhorum.
- How Peptides Are Expanding The Possibilities Of Drug Discovery
- The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
- How To Keep Your 'Big Bang' Platform Switch From Becoming A Big Bust
- FDA Rethinks Skin Sensitization Testing For Generic Transdermal And Topical Delivery Systems
- How Is Your Glass Supplier Adapting To Europe's Energy Crisis?
PHARMA ONLINE WHITE PAPERS
-
![GettyImages-1816178364-scientist-inspecting-quality-ipad]( "Avoiding The Pitfalls Of APQR")
Avoiding The Pitfalls Of APQRTraditional quality reviews often fall short in today’s data-heavy environment. A real-time, digital-first approach enables faster insights, stronger compliance, and more proactive quality management.
-
Advancing Drug Safety And Improving R&D Productivity With The Liver-Chip S112/10/2024
Explore how the Emulate Liver-Chip S1 revolutionizes predictive toxicology by mimicking human liver biology, achieving superior sensitivity and specificity.
-
Connecting Quality Management, Patient-Centricity, And Business Value2/18/2025
Examine why organizations must integrate data and processes to enhance quality and insights to improve operational efficiency, patient health, and regulatory compliance.
-
Antibiotic Potency Testing By Microbial Assay9/24/2026
Selecting a potency assay for antibiotic drug substances and products carries regulatory, operational, and lifecycle implications that extend well beyond the laboratory.
-
Overcoming The Obstacles Of Spray-Dried Dispersion Scale-Up9/9/2026
SDD scale-up introduces scale-dependent risks that threaten bioavailability, stability, and manufacturability. This white paper details a model-based framework for managing those risks from early feasibility through commercial production.
-
Choosing The Right CDMO For Substance Development And Manufacturing11/3/2026
Controlled substance programs demand licensing, closed-system custody, and inspection history well beyond GMP. Sponsors weighing partners must test technical depth against compliance infrastructure.
PHARMA ONLINE APP NOTES & CASE STUDIES
- Mammalian Expression
- Scaling Down For Success: Optimizing Single-Use Virus Filtration For Small-Scale Bioprocessing
- Monitoring Microbial Contamination Of Mammalian Cell Cultures
- Automating Mass Spectrometry Analysis To Accelerate Oligonucleotide Drug Development
- Efficient Clone Screening With Increased Process Control And Integrated Cell Health And Titer Measurements With The Cydem VT Automated Clone Screening System
NEWSLETTER ARCHIVE
- 11.10.26 -- What's Next For Oligo Manufacturing?
- 11.10.26 -- Why Early Evaluation Of Process Parameters Matters In OSD Scale-Up
- 11.09.26 -- Building A Fill-Finish Strategy That Lasts
- 11.06.26 -- Smarter Strategies For Complex Protein Manufacturing
- 11.05.26 -- Reduce Risk From Drug Formulation Through Commercial Launch
NEW FOR OUR READERS
INDUSTRY NEWS
-
![white coupon banner, great topic-GettyImages-2271702407]( "Let Your Voice Help Shape Pharma Manufacturing")
Let Your Voice Help Shape Pharma ManufacturingPharmaceutical Online hosts live virtual panels with industry experts on important topics and challenges, and we want to know what topics are important to you. Please consider taking a few minutes of your time to tell us what they are.
-
![rating service, satisfaction-GettyImages-2221603596]( "ISPE Announces 2026 FOYA Winners")
ISPE Announces 2026 FOYA WinnersThese awards recognize pharmaceutical and biopharmaceutical manufacturing projects that demonstrate excellence across innovation, operations, supply chain, Pharma 4.0, and social impact.
-
![FDA Logo on phone screen-GettyImages-2208861549]( "Høeg In, Pazdur Out At The FDA")
Høeg In, Pazdur Out At The FDAWhat an eventful week it has been at the FDA, with Richard Pazdur, M.D., resigning after weeks in his position as director of Center for Drug Research and Evaluation (CDER), and his vacancy being quickly filled by acting director Tracy Beth Høeg, M.D.
EDITORIAL COLLECTIONS
Our curated Editorial Collections bring expert insights together in one place, offering practical perspectives and actionable guidance to help you navigate complex decisions and improve performance.
More Editorial CollectionsSUPPLIER NEWS
-
Lonza Signs Agreement To Acquire US CDMO Network From Merck KGaA, Darmstadt, Germany, And Significantly Expands Its US Presence11/3/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today that it has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA, Darmstadt, Germany at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs.
-
Bracco To Build New Injectable Drug Manufacturing Facility In North Carolina11/2/2026
Bracco, a global leader in diagnostic imaging, today announced plans to invest $230 million to establish its first U.S. manufacturing facility for injectable contrast media in Sanford, North Carolina. Expected to create 200 jobs, the investment marks a significant milestone in Bracco's global manufacturing strategy, expanding production capacity and strengthening supply chain resilience in the United States, the company's largest market.
-
Lonza Further Expands Bioconjugation Manufacturing To Support Growing ADC Demand10/29/2026
Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today the further expansion of its integrated bioconjugation manufacturing offering. Lonza is combining the flexibility of mid-scale bioconjugation manufacturing with its previously announced large-scale bioconjugation expansion in Visp (CH), which will now include three multiproduct suites. Together, these capabilities will offer customers a scalable manufacturing pathway from clinical development through commercial supply for antibody-drug conjugates (ADCs) and other bioconjugates.
-
ROSS Portable High Shear Mixing System10/29/2026
-
Ardena Launches Online Biomarker Catalogue: 228 Markers, One Quote Request10/29/2026
Ardena has launched a searchable Biomarker Catalogue on its website, giving sponsors a faster route from biomarker selection to a bioanalysis quote.
